vs

Side-by-side financial comparison of Farmland Partners Inc. (FPI) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Farmland Partners Inc. is the larger business by last-quarter revenue ($20.7M vs $12.5M, roughly 1.7× Avidity Biosciences, Inc.). Farmland Partners Inc. runs the higher net margin — 103.4% vs -1398.3%, a 1501.7% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -3.5%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 31.4%).

Farmland Industries was the largest agricultural cooperative in North America when it eventually sold all of its assets in 2002–04. During its 74-year history, Farmland served its farmer membership as a diversified, integrated organization, playing a significant role in agricultural markets both domestically and worldwide.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

FPI vs RNA — Head-to-Head

Bigger by revenue
FPI
FPI
1.7× larger
FPI
$20.7M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+437.6% gap
RNA
434.0%
-3.5%
FPI
Higher net margin
FPI
FPI
1501.7% more per $
FPI
103.4%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
31.4%
FPI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FPI
FPI
RNA
RNA
Revenue
$20.7M
$12.5M
Net Profit
$21.4M
$-174.4M
Gross Margin
Operating Margin
-1513.5%
Net Margin
103.4%
-1398.3%
Revenue YoY
-3.5%
434.0%
Net Profit YoY
-63.5%
-117.0%
EPS (diluted)
$0.44
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FPI
FPI
RNA
RNA
Q4 25
$20.7M
Q3 25
$11.3M
$12.5M
Q2 25
$10.0M
$3.8M
Q1 25
$10.3M
$1.6M
Q4 24
$21.5M
$3.0M
Q3 24
$13.3M
$2.3M
Q2 24
$11.4M
$2.0M
Q1 24
$12.0M
$3.5M
Net Profit
FPI
FPI
RNA
RNA
Q4 25
$21.4M
Q3 25
$483.0K
$-174.4M
Q2 25
$7.6M
$-157.3M
Q1 25
$2.0M
$-115.8M
Q4 24
$58.7M
$-102.3M
Q3 24
$1.8M
$-80.4M
Q2 24
$-2.0M
$-70.8M
Q1 24
$1.4M
$-68.9M
Operating Margin
FPI
FPI
RNA
RNA
Q4 25
Q3 25
4.3%
-1513.5%
Q2 25
78.2%
-4448.7%
Q1 25
20.6%
-8360.9%
Q4 24
-4069.6%
Q3 24
13.9%
-4200.9%
Q2 24
-17.9%
-4040.4%
Q1 24
11.9%
-2178.6%
Net Margin
FPI
FPI
RNA
RNA
Q4 25
103.4%
Q3 25
4.3%
-1398.3%
Q2 25
76.3%
-4089.3%
Q1 25
19.9%
-7360.0%
Q4 24
273.6%
-3439.5%
Q3 24
13.5%
-3441.7%
Q2 24
-17.5%
-3461.8%
Q1 24
11.5%
-1943.4%
EPS (diluted)
FPI
FPI
RNA
RNA
Q4 25
$0.44
Q3 25
$0.00
$-1.27
Q2 25
$0.14
$-1.21
Q1 25
$0.03
$-0.90
Q4 24
$1.09
$-0.80
Q3 24
$0.02
$-0.65
Q2 24
$-0.06
$-0.65
Q1 24
$0.01
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FPI
FPI
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
$161.6M
Stockholders' EquityBook value
$467.4M
$1.9B
Total Assets
$719.1M
$2.1B
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FPI
FPI
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Total Debt
FPI
FPI
RNA
RNA
Q4 25
$161.6M
Q3 25
$170.4M
Q2 25
$193.4M
Q1 25
$202.6M
Q4 24
$204.6M
Q3 24
$394.0M
Q2 24
$393.0M
Q1 24
$383.0M
Stockholders' Equity
FPI
FPI
RNA
RNA
Q4 25
$467.4M
Q3 25
$457.3M
$1.9B
Q2 25
$473.5M
$1.2B
Q1 25
$492.2M
$1.3B
Q4 24
$494.6M
$1.4B
Q3 24
$519.4M
$1.5B
Q2 24
$521.5M
$1.2B
Q1 24
$526.7M
$830.9M
Total Assets
FPI
FPI
RNA
RNA
Q4 25
$719.1M
Q3 25
$738.5M
$2.1B
Q2 25
$776.7M
$1.4B
Q1 25
$810.5M
$1.5B
Q4 24
$869.6M
$1.6B
Q3 24
$1.0B
$1.6B
Q2 24
$1.0B
$1.3B
Q1 24
$1.0B
$951.5M
Debt / Equity
FPI
FPI
RNA
RNA
Q4 25
0.35×
Q3 25
0.37×
Q2 25
0.41×
Q1 25
0.41×
Q4 24
0.41×
Q3 24
0.76×
Q2 24
0.75×
Q1 24
0.73×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FPI
FPI
RNA
RNA
Operating Cash FlowLast quarter
$17.4M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
0.81×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FPI
FPI
RNA
RNA
Q4 25
$17.4M
Q3 25
$-2.0M
$-156.2M
Q2 25
$-2.2M
$-199.7M
Q1 25
$6.4M
$-124.8M
Q4 24
$16.1M
$-99.9M
Q3 24
$-4.3M
$-65.6M
Q2 24
$-6.1M
$-65.0M
Q1 24
$11.9M
$-70.4M
Free Cash Flow
FPI
FPI
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
FPI
FPI
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
FPI
FPI
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
FPI
FPI
RNA
RNA
Q4 25
0.81×
Q3 25
-4.04×
Q2 25
-0.29×
Q1 25
3.12×
Q4 24
0.27×
Q3 24
-2.39×
Q2 24
Q1 24
8.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons